Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 23, 2026.

Metals and Neurodegeneration

Pan Chen, Mahfuzur Rahman Miah, Michael Aschner

F1000Research · 2016 · Review

doi:10.12688/f1000research.7431.1

Abstract

Metals play important roles in the human body, maintaining cell structure and regulating gene expression, neurotransmission, and antioxidant response, to name a few. However, excessive metal accumulation in the nervous system may be toxic, inducing oxidative stress, disrupting mitochondrial function, and impairing the activity of numerous enzymes. Damage caused by metal accumulation may result in permanent injuries, including severe neurological disorders. Epidemiological and clinical studies have shown a strong correlation between aberrant metal exposure and a number of neurological diseases, including Alzheimer’s disease, amyotrophic lateral sclerosis, autism spectrum disorders, Guillain–Barré disease, Gulf War syndrome, Huntington’s disease, multiple sclerosis, Parkinson’s disease, and Wilson’s disease. Here, we briefly survey the literature relating to the role of metals in neurodegeneration.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Metals are a component of the earth’s crust and exist in the water, air, and a variety of ecosystems. They can generally be divided into two groups: essential and non-essential metals. Essential metals include chromium, cobalt, copper (Cu), iron (Fe), lithium, magnesium, manganese (Mn), nickel, selenium, and zinc (Zn). These trace metals usually act as a cofactor of enzymes to regulate cellular activities. For example, Mn is required for the activity of arginase, hydrolases, lyases, glutamine synthetase, and superoxide dismutase (SOD). Thus, these metals are involved in a whole host of physiological processes, such as electron transport, oxygen transportation, protein modification, neurotransmitter synthesis,, redox reactions, immune responses, cell adhesion, and protein and carbohydrate metabolism, to name a few. Metals accumulate in the brain, indicating their important roles in the nervous system. Deficiency of these metals has been associated with various neurological diseases. For example, Fe deficiency is related to restless leg syndrome, pediatric stroke, breath-holding spells, pseudotumor cerebri, and cranial nerve palsy,.

Although metals are important for animals and plants, they usually are required in trace amounts. Excessive metal levels accumulate in various organs, including the brain. Elevated levels of metals may induce various detrimental intracellular events, including oxidative stress, mitochondrial dysfunction, DNA fragmentation, protein misfolding, endoplasmic reticulum (ER) stress, autophagy dysregulation, and activation of apoptosis –. These effects may alter neurotransmission and lead to neurodegeneration, which can manifest as cognitive problems, movement disorders, and learning and memory dysfunction. To date, metal-induced neurotoxicity has been associated with multiple neurological diseases in humans, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), autism spectrum disorders (ASDs), Guillain–Barré disease (GBD), Gulf War syndrome (GWS), Huntington’s disease (HD), manganism, multiple sclerosis, Parkinson’s disease (PD), and Wilson’s disease (WD), –. Here, we address the neurotoxicity of several metals as well as the human neurological diseases associated with these metals.

Copper

Cu is an essential trace element and a transition metal required for physiological activities in mammals. Cu acts as a cofactor of various enzymes (such as cytochrome c oxidase and SODs), playing an important role in electron transport, oxygen transportation, protein modification, and neurotransmitter synthesis,. However, elevated Cu levels may result in the generation of reactive oxygen species (ROS), DNA damage, and mitochondrial dysfunction. Excessive Cu has been associated with AD, ALS, HD, PD, WD, and prion diseases in humans,,. Cu may enhance the self-aggregation of amyloid precursor proteins and β-amyloid peptide, and increased levels of Cu in cerebrospinal fluid have been found in some patients with AD. Similarly, Cu interacts with α-synuclein and promotes its aggregation, which could result in PD. Gain-of-function mutations in Cu/Zn-SOD might result in oxidative stress through production of free radicals, possibly leading to motor neuron degeneration in patients with ALS,. It is also noteworthy that metals such as Cu and Zn are controlled by overlapping proteins, such as metallothionein. Notably, Cu levels are also higher in HD patients compared with controls.

Prion diseases are characterized by altered structure, changing from a normal cellular isoform (PrP C) to an abnormal scrapie isoform (PrP Sc), which contains high-affinity Cu-binding sites. The binding of Cu enhances the stability of prion proteins, making them resistant to proteasomal degradation and leading to neurodegeneration. However, the binding capability of Cu to the prions does not explain its role in the progression of prion disease. It is noteworthy that metal mixtures, such as silver and Cu, have been shown to change the affinity of PrP C to Cu. In addition, an inverse correlation between Cu and Mn has been noted in patients with prion disease,. Cu does not appear in the formation of PrP Sc, and increases in Cu in the diet have been associated with delays in the onset of prion disease –. Given both the beneficial and neurotoxic effect of Cu in the brain, new biomarkers and improved measurement of Cu trafficking are needed to predict potential risks, and novel therapeutics need to be developed for Cu-induced neurotoxicity and cognitive dysfunction.

Iron

Fe is an essential metal, serving as a cofactor for a variety of enzymes and proteins, most prominently hemoglobin. Fe’s ability to interact with oxygen makes it important for oxygen transport in the cellular respiration pathway as well as for a variety of redox reactions. Exposure to Fe is primarily through food consumption, although toxic levels of Fe accumulation are usually due to disrupted Fe homeostasis and metabolism in the brain,. Hemolysis, the breakdown of red blood cells, in the young brain with an immature blood-brain barrier (BBB) can also lead to aberrant Fe accumulation, which results in neuronal damages. Fe accumulation can cause increased ROS levels, lipid peroxidation, protein oxidation, DNA damage, dopamine autoxidation, and mitochondrial fragmentation –.

Fe dyshomeostasis has been linked to a variety of neurological disorders, including PD, AD, HD, ALS, and neurodegeneration with brain iron accumulation (NBIA), –. Increased brain Fe deposition has been observed and Fe has been shown to promote aggregation of α-synuclein, which is found in patients with PD –. Increased Fe accumulation in the brains of patients with AD has also been observed along with evidence of Fe contributing to β-amyloid aberrant aggregation and toxicity, a hallmark of the disease –. Increased Fe is also seen in patients with HD, and Huntingtin (htt), the central protein in HD pathology, is thought to mediate Fe homeostasis,. Patients with ALS show accumulation of Fe in the motor cortex, and SOD-1, a gene mutated in patients with ALS, has been shown to cause damage via Fe-induced oxidative stress –. Finally, NBIA, as the name implies, is an umbrella of heterogeneous neurodegenerative diseases that present with simultaneous Fe accumulation. Genetic studies indicate that the majority of the genes mutated in patients with NBIA are related not to Fe homeostasis but rather to autophagy, mitochondria metabolism, and lipid metabolism. This suggests that Fe accumulation in patients with NBIA may not be the initial insult of a disease pathology but rather a downstream phenomenon that serves to exacerbate already-present issues. Alternatively, these genes may have currently unknown Fe regulatory functions that have yet to be examined. This question of whether Fe is part of the cause of a disease, or vice versa, continues to be a point of controversy.

Manganese

Mn is a trace element and nutrient necessary for biological processes within the human body. Low concentrations of Mn are essential to the body; Mn serves as a cofactor in a variety of metalloproteins, including MnSOD and arginase, and is important in the function of a variety of enzymes, including glutamine synthetase, hydrolases, and lyases,. Exposure to high levels of Mn may be toxic. Consumption of food is the primary route for entrance into the body,. Mn can be inhaled as well, and this serves as an occupational hazard for those who work in welding and mining industries,,. Soy-based infant formula has been suggested as an exposure route for excess Mn, which may lead to mild neurological defects during critical stages of development,. Chronic Mn exposure can cause debilitating neurological effects. Mn overexposure leads to a type of parkinsonism known as manganism and has been suggested as part of PD etiology as well,. Manganism is characterized by tremors, lethargy, and speech impediments, with the occasional accompaniment of psychosis,. Mn is elevated in dopaminergic (DAergic) neurons of the substantia nigra, providing a possible basis for the motor deficits observed in manganism. Elevated Mn has been shown to affect a variety of cellular processes, including increased levels of transcription for ER-related genes, ROS production, mitochondrial dysfunction, autophagy, altered acetylcholinesterase (AChE) activity, changes in cyclic AMP (cAMP) signaling, iron dyshomeostatis, and dysfunctional astrocytic activity. Many markers of programmed cell death, including increased TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining, internucleosomal DNA cleavage, activation of JNK, p38, the apoptotic initiator caspase-12, and pro-apoptotic effector caspase-3, have been observed in neurons in the presence of Mn exposure,. Specifically, Mn has been shown to induce proteolytic cleavage of protein kinase C-δ (PKC-δ) as an essential player in Mn-induced neuronal death and in the neuroprotective activity of α-synuclein protein aggregation upon chronic Mn exposure –. The induction of apoptosis is possibly mediated through ER stress and autophagy. In DAergic SH-SY5Y cells exposed to Mn, the levels of ER stress response proteins, including the ER chaperone GRP94 and the pro-apoptotic GADD153/CHOP protein, as well as phosphorylated eIF2α (eukaryotic translation initiation factor 2α) are increased significantly. In Mn-treated DAergic neurons, increased abnormal lysosomes, decreased expression of autophagy-related protein Beclin1, and activation of mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70s6k) signaling have been observed, possibly leading to DAergic neurodegeneration.

In addition, PD-related mutant genes (such as ATPase 12A3) have been shown to alter Mn homeostasis, supporting the link between Mn dyshomeostasis and PD. Interestingly, the newly identified Mn transporter SLC30A10 has been associated with dystonia, parkinsonism, and hypermanganesemia when mutated –. This protein is expressed at high levels in the liver and the basal ganglia. Loss-of-function mutants prevent Mn excretion and result in high levels of plasma Mn, which eventually accumulates in the basal ganglia of the brain,. Indeed, Mn can also catalyze the autoxidation of dopamine, whose toxic metabolites can wreak havoc on DAergic cells, suggestive of similar pathology between PD and manganism,. In regard to prion disease, a protective role for prion protein against Mn neurotoxicity has been suggested upon short-term exposure to Mn, although prolonged Mn exposure was shown to promote the stabilization and aggregation of the infectious protein,. Although Mn is an essential metal, Mn homeostatic and signaling pathways are still being delineated, and further investigation may give insight into not only Mn regulation but also manganism and other forms of parkinsonism.

Zinc

Zn is an essential trace metal (the second most abundant transition metal after Fe) required for humans and many other living organisms. It is a cofactor for over 300 enzymes and metalloproteins, regulating gene transcription and the antioxidant response. The majority of Zn is in the testes, muscle, liver, and brain. In childhood, Zn deficiency affects mental and physical development as well as learning abilities,. However, excess levels of Zn suppresses Cu and Fe absorption, promoting ROS production in the mitochondria, disrupting activities of metabolic enzymes, and activating apoptotic processes. Disruption of Zn homeostasis has been associated with AD, brain trauma, cerebral ischemia, epilepsy, and vascular-type dementia (VD),. At low concentrations (a few micromolar), Zn suppresses β-amyloid-induced neurotoxicity by selectively precipitating aggregation intermediates,. However, at high levels, the binding of Zn to β-amyloid may enhance formation of fibrillar β-amyloid aggregation, leading to neurodegeneration,. Zn also plays a critical role in ischemia-induced neuronal death and the pathogenesis of VD, evidenced by a correlation of increased Zn concentration with glutamate being packaged into synaptic clefts during membrane depolarization under ischemic conditions,. Future research should assess the intracellular activities of supplemental and neurotoxic Zn in the nervous system and investigate optimal Zn doses needed for different groups of people, especially infants and children.

Aluminum

Aluminum (Al) is the third most abundant element and the most abundant metal in the earth’s crust. It has a wide range of uses, including in food preservation, cans, cookware, cars, and vaccine adjuvants, to name a few. The exact function of Al in animals remains unknown. Al is highly reactive with carbon and oxygen, making it toxic to living organisms. In humans, Al from dietary intake and environmental exposure is rapidly cleared by the kidney. However, Al salts in vaccine adjuvants remain biologically available and accumulate in the nervous system. Al has been associated with AD, ALS, ASDs, GBD, multiple sclerosis, and GWS in humans,. In patients with dialysis-associated encephalopathy, Al accumulation was found in the brain together with β-amyloid peptide accumulation,. Interestingly, the symptoms quickly abated after removal of Al from the dialysis solution. Recently, a meta-analysis showed that chronic Al exposure increased the risk of AD by approximately 70%. In addition, a correlation between the number of children with ASD and exposure to Al-adjuvanted vaccines was observed; higher levels of Al were found in the hair, blood, and urine of children with autism. In mice, injection of Al hydroxide results in loss of long-term memory, increased anxiety, and neuronal death in the spinal cord and motor cortex. The neurological damage may be due to oxidative stress, and mitochondrial dysfunction –. However, the results of many of these reports do not address confounding variables such as genetic backgrounds that may predispose an organism to the susceptibility of Al-induced neurological damage. Taken together, genetic polymorphisms combined with environmental factors likely trigger Al-induced neurotoxicity. Future studies could be profitably directed at investigating the relationship between Al exposure and genetic risk factors of these neurological diseases.

Arsenic

Commonly used as a wood preservative in the past and known for its contamination of groundwater, Arsenic (As) is a toxic metalloid and well-known carcinogen, which over 200 million people worldwide are chronically exposed to –. Research suggests that As exposure induces mitochondrial oxidative stress, imbalance of intracellular Ca 2+, disruption in ATP production, altered membrane potential, changes in cytoskeletal morphology, and neuronal cell death, among other effects,. Studies have shown that early-life exposure to As can cause lower brain weight and a reduction in glia and neurons. As exposure is associated with AD and ALS,. Dimethylarsenic acid, a metabolite of As in humans, has been shown to increase β-amyloid levels, a key feature of AD. Translocation of neurofilament (NF) was inhibited by As exposure and is linked to decreased NF content at peripheral nerves. This may be important in understanding the aberrant NF distribution that is a hallmark of ALS. Owing to the persistent exposure of As to the human population, further investigation into the mechanisms of As poisoning is warranted.

Cadmium

Cadmium (Cd) is a non-essential transition heavy metal and known human carcinogen. It can enter the peripheral and central neurons from the nasal mucosa or the olfactory bulb, which damages permeability of the BBB. Miners, welders, smokers, and workers in battery production are at risk of high Cd exposure. In cells, Cd can induce oxidative stress, suppress gene expression, and inhibit DNA damage repair and apoptosis. Chronic exposure to Cd may severely interfere with normal function of the nervous system, and infants and children are more susceptible than adults. Cd is a possible etiological factor of neurodegenerative diseases, including AD and PD. The symptoms include headache, megrim, olfactory dysfunction, slowing of vasomotor functioning, decreased equilibrium and learning ability, and PD-like symptoms. Jiang et al. found that Cd accelerates self-aggregation of Alzheimer’s tau peptide R3, and it has been reported in a case study that a 64-year-old man developed PD symptoms 3 months after acute exposure to Cd fumes. In zebrafish, Cd exposure resulted in decreased head size and unclear brain subdivision boundaries in the mid-hindbrain region. In addition, Cd exposure has been shown to result in morphological changes of rat cortical neurons (axons and dendrites) and inhibited neurite outgrowth in PC12 cells. Owing to Cd’s role as a carcinogen, the neurotoxicity induced by Cd is underestimated. Thus, future research should further investigate the mechanism of neurotoxic effect of Cd, especially that of chronic low-level Cd exposure.

Lead

Lead (Pb) is a non-essential heavy metal and a ubiquitously present pollutant in the ecosystem. In humans, inhalation and oral ingestion are the major routes of Pb exposure. In the body, Pb can be excreted in urine and bile, and some Pb can bind to red blood cells and eventually accumulate in bone. Pb exposure results in oxidative stress, mitochondrial dysfunction, changes to the Golgi apparatus, and increased gliofilaments in astrocytes. It also disrupts Ca 2+ homeostasis, interferes with the phosphorylation of PKC, and decreases nitric oxide production. The main target of Pb-induced toxicity is the nervous system, and children are particularly sensitive to Pb intoxication. The hippocampus is the primary region of Pb accumulation, although the metal may also accumulate in several other brain regions. It has been reported that Pb exposure results in deficits in intelligence, memory, executive functioning and attention, processing speed, language, emotion, and visuospatial and motor skills. For example, in children, Pb exposure results in decreased intellectual ability in a dose-dependent manner,, impaired verbal concept formation, grammatical reasoning difficulty, poor command following, and so on. In adults, workers with occupational exposure to Pb have shown impairment of verbal memory and visual memory performance, lower decision-making speed, deficit in visuomotor coordination, and increased interpersonal conflict. Given the severe health issues caused by Pb, novel techniques for early diagnosis of Pb exposure (especially during pregnancy and childhood) and effective treatment after Pb exposure should be the focus of future research on Pb.

Methylmercury

Methylmercury (MeHg) is a xenobiotic toxic organic metal compound derived from inorganic mercury (Hg). Hg finds itself in our environment primarily through anthropogenic sources such as industrial waste, coal mining, and natural sources such as volcanoes and forest fires that release Hg back into the atmosphere. Hg that pollutes the aquatic arena through these paths can be readily methylated into MeHg by sulfate-reducing bacteria and a variety of other anaerobic bacteria. MeHg bioaccumulates in the aquatic food chain, and seafood consumption remains one of the main forms of exposure for humans. MeHg has a high affinity for sulfur and can cross the BBB by binding onto thiol groups of proteins; it can also bind to lone cysteine, mimicking the structure of methionine, allowing for the possibility of uptake by amino acid transporters,. MeHg can accumulate in the brain and has led to epidemics in the past at Minamata Bay and Iraq, where those affected, particularly children, presented with a variety of central nervous system (CNS) disorders, including ataxia, paralysis, retardation, dysarthria, dysesthesia, and cerebral palsy. A case study of autopsies in a family that was exposed to high levels of MeHg revealed that exposure to MeHg leads to inorganic Hg buildup in the brain. Furthermore, cerebellar and occipital lobe atrophy was observed in patients who had experienced motor and vision issues. Differential distribution of Hg content was also observed, and the greatest amounts were in the occipital lobe and cerebellum and basal ganglia, reflective of the areas important for vision and movement. At the cellular level, MeHg is known to affect a variety of neuronal activities including dopamine metabolism, neural stem cell differentiation, generation of ROS, increased calcium influx, aberrant autophagy,, DNA damage, and mitochondrial dysfunction. In addition, MeHg exposure has been shown to increase β-amyloid in the hippocampus and decrease it in the cerebrospinal fluid, both hallmarks of AD. Currently, treatment options for those exposed to MeHg are not prevalent. Prevention of exposure has been the major development in the past few decades whereby government advisories have been established to inform and protect their respective populations. Limitations on fully understanding the effect of MeHg on the CNS include the confounding beneficial nature of seafood by which MeHg usually enters the human body.

Thallium

Thallium (Tl), a naturally occurring trace element, is an extremely toxic heavy metal, sparsely found in the earth’s crust,. Sources of Tl include industrial processing of cement and non-industrial means such as rodenticide and eating foods from contaminated soils. Tl can make its way into the body not only through consumption but also via the skin and inhalation,. Non-neurological symptoms include alopecia, hepatic dysfunction, gastroenteritis, and Mees’ lines, and CNS-related disorders include polyneuropathy, cranial nerve deficits, paresthesia, loss of sensation, ataxia, and psychosis, –. Victims of Tl poisoning complain of peripheral neuropathy,. It has been shown that Tl exposure can lead to inhibition of AChE, an enzyme catalyzing breakdown of the neurotransmitter acetylcholine (Ach), which may explain peripheral neuropathy. Studies have shown that Tl concentrations in the brain are lower than in other parts of the body, and that the highest concentrations in the brain are in the hypothalamus. Tl + interferes with a host of K +-dependent processes because of similarities in size and the univalent nature of the two ions; one of the affected processes is ATP generation,,. At the cellular level, higher levels of Tl have been shown to cause a decrease in ATP production, increase in ROS formation, glutathione oxidation, and decreases in dopamine and serotonin levels in the brain,,. Owing to available treatments for this xenobiotic metal and lack of major risk of exposure to the general public, clarity in signaling pathways remains an issue. Furthermore, the complicated symptoms may cause misdiagnosis of Tl poisoning, which points to the need for health professionals to be more aware of the features of Tl-induced poisoning and neurotoxicity.

Neurotoxicity induced by metal mixture

The neurotoxicity of metals is usually studied on an individual metal basis. However, the fact is that we are exposed to an environment of mixed metals, which makes it more complicated to study. It is noteworthy that changes in the level of one metal may have significant effect on the homeostasis of other metals, given that various metals (such as Mn, Fe, Cd, Cu, and Zn) are transported by shared transporters or controlled by overlapping signaling pathways. There are limited studies focusing on the combined effect of mixed metal exposure. The neurotoxicity of Pb with other metals (As, Cd, Hg, and Mn) is well studied. Prenatal exposure to Pb and As tends to increase the probability of intellectual disability when compared with exposure to a single metal. High Pb levels might affect mental and psychomotor development in children with high prenatal Cd exposure,. Co-exposure to high levels of Pb and Mn together in the prenatal period led to larger deficits in cognition and language development in children at two years of age compared with single-metal exposure. Pb exposure was associated with lower IQ scores but only among children with high blood Mn levels. In contrast to the synergetic effect between Pb and As, Pb along with Cd, Mn, or Hg exposure tends to work in an antagonistic way, given that the combined effect on cognitive deficits caused by MeHg and Pb exposure was less than additive.

In rodents, it has been reported that co-administration of two metals might increase the retention and redistribution of individual metals. Co-exposure of Se and Hg increased the retention of both metals and resulted in a redistribution of Hg in the blood and organs. Chandra et al. reported that oral intake of Mn and intraperitoneal administration of Pb in rats resulted in alternations in motor activity, learning ability, and biogenic amine levels and Pb levels in the brain, which were more severe than in rats exposed to either Mn or Pb alone. Similarly, rat brain weight decreased to a larger degree under conditions of co-exposure to both Mn and Pb than with either metal alone. An interaction of As/Pb has been reported to affect the central monaminergic systems in mice. The As/Pb mixture enhanced Pb accumulation but reduced As accumulation in the brain, decreased norepinephrine levels in the hippocampus, and increased serotonin levels in the midbrain and frontal cortex, when compared with single-metal exposure. In rats with oral consumption of mining waste (containing As, Cd, Mn, and Pb), accumulation of As and Mn was found in the brain, and dopamine release decreased with a long-standing polarization, when compared with the control. Mn may exacerbate the well-documented neurotoxic effects of Pb among children, particularly at younger ages. The metal mixture (As, Mn, and Pb) significantly decreased rat motor parameters compared with the single-metal exposure. Given that humans are exposed to multiple metals simultaneously in real life and neurotoxicity is commonly accompanied with metal overexposure, more studies are needed to investigate the health impacts of metal mixture in the near future to better understand their synergetic or antagonistic effect.

Treatment for metal-induced neurotoxicity

Upon occurrence of metal poisoning, patients should be transferred out of the exposing environment first, followed by gastrointestinal decontamination. For example, a rapid decrease in blood plasma Mn levels has been noticed with discontinued Mn supplementation in children with cholestasis receiving total parental nutrition. However, this therapy might not work well for patients with chronic metal exposure, given that metals have already accumulated in the nervous system, bones, and other tissues rather than in the plasma. Currently, chelation therapy is a common treatment to remove additional metals in the body for both chronic and acute metal poisoning. Chelators include British antilewisite (BAL), succimer (DMSA), Prussian blue, calcium disodium edetate (CaNa 2EDTA), and D-Penicillamine (Cuprimine). However, the chelators themselves may have adverse effects, such as headache, fatigue, renal failure, nasal congestion, gastrointestinal side effects, and life-threatening hypocalcemia, to name a few. The specificity of these chelators and the dosage to use are the major concerns when performing chelation therapy. The discovery of specific metal exporters provides novel therapeutics for metal-induced neurotoxicity. For example, SLC30A10 is a newly identified Mn transporter facilitating efflux of excessive intracellular Mn; patients with mutations in the gene presented with dystonia, hypermanganesemia, parkinsonism, and manganism,,,. Although a study of its complete substrates has not been finished, this protein seems to transport Mn exclusively,. Pharmaceutical compounds enhancing the exporting activity of SLC30A10 will promote specifically Mn efflux but leave other metals untouched. This can bypass the side effects caused by chelation to a great degree. Unfortunately, specific transporters for different metals like SLC30A10 for Mn remain largely unknown. Future studies to identify metal-specific transporters are in great need to design therapeutics to treat metal-induced toxicity.

Conclusions and future directions

Metals play an important role in our daily life as they are widely involved in numerous enzymatic activities. Some of them are essential at trace amounts; however, excessive amounts in the human body usually result in neurotoxicity. AD, ALS, autism, and PD are commonly associated with metal overexposure. Once metals have accumulated in the nervous system, oxidative stress, mitochondrial dysfunction, and protein misfolding are the most common deficits associated with metal-induced toxicity –. Once injured, neurons have to expend greater energy to synthesize neurotransmitters and maintain homeostasis. The increased burden combined with the neurotoxicity may lead to neuronal death. When some neurons are lost, the job has to be passed on to other neurons, initiating a vicious cycle of toxicity. Given that the nervous system does not regenerate as well as other systems do, the neurodegeneration and impairments usually become progressive with age, as typically seen in AD and PD. With the increase of lifespan among the general population, there is arguably a longer duration of exposure to greater levels of metals for individuals and potential increase in frequency of occurrence of neurological diseases. Accordingly, there is a growing demand to investigate the neurotoxicity resulting from metal exposure. Future studies need to focus more on the joint effect of metal mixture exposure, identifying specific transporters of each metal as well as developing target-specific therapeutics for patients with metal poisoning.

References 168

  1. 1.

    Chen P Parmalee N Aschner M: Genetic factors and manganese-induced neurotoxicity. Front Genet. 2014;5:265.

    Not in our library10.3389/fgene.2014.00265

  2. 2.

    Banci L: Metallomics and the Cell. Dordrecht: Springer Netherlands;2013; 12

    Not in our library10.1007/978-94-007-5561-1

  3. 3.

    Desai V Kaler SG: Role of copper in human neurological disorders. Am J Clin Nutr. 2008;88(3):855S–8S.

    Not in our library10.1093/ajcn/88.3.855s

  4. 4.

    Rangarajan S D'Souza GA: Restless legs syndrome in Indian patients having iron deficiency anemia in a tertiary care hospital. Sleep Med. 2007;8(3):247–51.

    Not in our library10.1016/j.sleep.2006.10.004

  5. 5.

    Yager JY Hartfield DS: Neurologic manifestations of iron deficiency in childhood. Pediatr Neurol. 2002;27(2):85–92.

    Not in our library10.1016/s0887-8994(02)00417-4

  6. 6.

    Wright RO Baccarelli A: Metals and neurotoxicology. J Nutr. 2007;137(12):2809–13.

    Not in our library10.1093/jn/137.12.2809

  7. 7.

    Angeli S Barhydt T Jacobs R: Manganese disturbs metal and protein homeostasis in Caenorhabditis elegans. Metallomics. 2014;6(10):1816–23.

    Not in our library10.1039/c4mt00168k

  8. 8.

    Zhang J Cao R Cai T: The role of autophagy dysregulation in manganese-induced dopaminergic neurodegeneration. Neurotox Res. 2013;24(4):478–90.

    Not in our library10.1007/s12640-013-9392-5

  9. 9.

    Seo YA Li Y Wessling-Resnick M: Iron depletion increases manganese uptake and potentiates apoptosis through ER stress. Neurotoxicology. 2013;38:67–73.

    Not in our library10.1016/j.neuro.2013.06.002

  10. 10.

    Gunter TE Gerstner B Lester T: An analysis of the effects of Mn 2+ on oxidative phosphorylation in liver, brain, and heart mitochondria using state 3 oxidation rate assays. Toxicol Appl Pharmacol. 2010;249(1):65–75.

    Not in our library10.1016/j.taap.2010.08.018

  11. 11.

    Malecki EA: Manganese toxicity is associated with mitochondrial dysfunction and DNA fragmentation in rat primary striatal neurons. Brain Res Bull. 2001;55(2):225–8.

    Not in our library10.1016/s0361-9230(01)00456-7

  12. 12.

    Bondy SC Guo-Ross SX Pien J: Mechanisms underlying the aluminum-induced potentiation of the pro-oxidant properties of transition metals. Neurotoxicology. 1998;19(1):65–71.

    Not in our library

  13. 13.

    Strong MJ Garruto RM Joshi JG: Can the mechanisms of aluminum neurotoxicity be integrated into a unified scheme? J Toxicol Environ Health. 1996;48(6):599–613.

    Not in our library10.1080/009841096161096

  14. 14.

    Shaw CA Tomljenovic L: Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunol Res. 2013;56(2–3):304–16.

    Not in our library10.1007/s12026-013-8403-1

  15. 15.

    Authier FJ Cherin P Creange A: Central nervous system disease in patients with macrophagic myofasciitis. Brain. 2001;124(Pt 5):974–83.

    Not in our library10.1093/brain/124.5.974

  16. 16.

    Strausak D Mercer JF Dieter HH: Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull. 2001;55(2):175–85.

    Not in our library10.1016/s0361-9230(01)00454-3

  17. 17.

    Okuda B Iwamoto Y Tachibana H: Parkinsonism after acute cadmium poisoning. Clin Neurol Neurosurg. 1997;99(4):263–5.

    Not in our library10.1016/s0303-8467(97)00090-5

  18. 18.

    Chen P Chakraborty S Peres TV: Manganese-induced Neurotoxicity: From C. elegans to Humans. Toxicol Res (Camb). 2015;4(2):191–202.

    Not in our library10.1039/c4tx00127c

  19. 19.

    Valensin D Padula EM Hecel A: Specific binding modes of Cu(I) and Ag(I) with neurotoxic domain of the human prion protein. J Inorg Biochem. 2016;155:26–35.

    Not in our library10.1016/j.jinorgbio.2015.11.015

  20. 20.

    Ha C Ryu J Park CB: Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry. 2007;46(20):6118–25.

    Not in our library10.1021/bi7000032

  21. 21.

    Roos PM Vesterberg O Nordberg M: Metals in motor neuron diseases. Exp Biol Med (Maywood). 2006;231(9):1481–7.

    Not in our library10.1177/153537020623100906

  22. 22.

    Rasia RM Bertoncini CW Marsh D: Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proc Natl Acad Sci U S A. 2005;102(12):4294–9.

    Not in our library10.1073/pnas.0407881102

  23. 23.

    Isani G Carpenè E: Metallothioneins, unconventional proteins from unconventional animals: a long journey from nematodes to mammals. Biomolecules. 2014;4(2):435–57.

    Not in our library10.3390/biom4020435

  24. 24.
  25. 25.

    Thackray AM Knight R Haswell SJ: Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J. 2002;362(Pt 1):253–8.

    Not in our library10.1042/bj3620253

  26. 26.

    Wong BS Chen SG Colucci M: Aberrant metal binding by prion protein in human prion disease. J Neurochem. 2001;78(6):1400–8.

    Not in our library10.1046/j.1471-4159.2001.00522.x

  27. 27.

    Quaglio E Chiesa R Harris DA: Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem. 2001;276(14):11432–8.

    Not in our library10.1074/jbc.m009666200

  28. 28.

    Pass R Frudd K Barnett JP: Prion infection in cells is abolished by a mutated manganese transporter but shows no relation to zinc. Mol Cell Neurosci. 2015;68:186–93.

    Not in our library10.1016/j.mcn.2015.08.004

  29. 29.

    Hijazi N Shaked Y Rosenmann H: Copper binding to PrP C may inhibit prion disease propagation. Brain Res. 2003;993(1–2):192–200.

    Not in our library10.1016/j.brainres.2003.09.014

  30. 30.

    Biasiotto G Di Lorenzo D Archetti S: Iron and Neurodegeneration: Is Ferritinophagy the Link? Mol Neurobiol. 2015;1–33.

    Not in our library10.1007/s12035-015-9473-y

  31. 31.

    Sheftel AD Mason AB Ponka P: The long history of iron in the Universe and in health and disease. Biochim Biophys Acta. 2012;1820(3):161–87.

    Not in our library10.1016/j.bbagen.2011.08.002

  32. 32.

    Chatterjee S Sarkar S Bhattacharya S: Toxic metals and autophagy. Chem Res Toxicol. 2014;27(11):1887–900.

    Not in our library10.1021/tx500264s

  33. 33.
  34. 34.

    Akar E Ünalp A Diniz G: Investigation of iron's neurotoxicity during cerebral maturation in the neonatal rat model of haemolysis. Folia Neuropathol. 2015;53(3):262–9.

    Not in our library10.5114/fn.2015.54623

  35. 35.

    Nohl H Kozlov AV Gille L: Cell respiration and formation of reactive oxygen species: facts and artefacts. Biochem Soc Trans. 2003;31(Pt 6):1308–11.

    Not in our library10.1042/bst0311308

  36. 36.

    Salvador GA Uranga RM Giusto NM: Iron and mechanisms of neurotoxicity. Int J Alzheimers Dis. 2010;2011: 720658.

    Not in our library10.4061/2011/720658

  37. 37.

    Shen XM Dryhurst G: Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. Chem Res Toxicol. 1998;11(7):824–37.

    Not in our library10.1021/tx980036t

  38. 38.

    Park J Lee DG Kim B: Iron overload triggers mitochondrial fragmentation via calcineurin-sensitive signals in HT-22 hippocampal neuron cells. Toxicology. 2015;337:39–46.

    Not in our library10.1016/j.tox.2015.08.009

  39. 39.

    Zucca FA Segura-Aguilar J Ferrari E: Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol. 2015; pii: S0301-0082(15)00101-X.

    Not in our library10.1016/j.pneurobio.2015.09.012

  40. 40.

    Greenough MA Camakaris J Bush AI: Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int. 2013;62(5):540–55.

    Not in our library10.1016/j.neuint.2012.08.014

  41. 41.

    Meyer E Kurian MA Hayflick SJ: Neurodegeneration with Brain Iron Accumulation: Genetic Diversity and Pathophysiological Mechanisms. Annu Rev Genomics Hum Genet. 2015;16:257–79.

    Not in our library10.1146/annurev-genom-090314-025011

  42. 42.

    Doorn JM Kruer MC: Newly characterized forms of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci Rep. 2013;13(12):413.

    Not in our library10.1007/s11910-013-0413-9

  43. 43.

    Pyatigorskaya N Sharman M Corvol JC: High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry. Mov Disord. 2015;30(8):1077–84.

    Not in our library10.1002/mds.26218

  44. 44.

    Febbraro F Giorgi M Caldarola S: α-Synuclein expression is modulated at the translational level by iron. Neuroreport. 2012;23(9):576–80.

    Not in our library10.1097/wnr.0b013e328354a1f0

  45. 45.

    Uversky VN Li J Fink AL: Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276(47):44284–96.

    Not in our library10.1074/jbc.m105343200

  46. 46.

    Ayton S Lei P Bush AI: Metallostasis in Alzheimer's disease. Free Radic Biol Med. 2013;62:76–89.

    Not in our library10.1016/j.freeradbiomed.2012.10.558

  47. 47.

    Banerjee P Sahoo A Anand S: Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: protective action of negletein. Neuromolecular Med. 2014;16(4):787–98.

    Not in our library10.1007/s12017-014-8328-4

  48. 48.

    Liu B Moloney A Meehan S: Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem. 2011;286(6):4248–56.

    Not in our library10.1074/jbc.m110.158980

  49. 49.

    Bartzokis G Cummings J Perlman S: Increased basal ganglia iron levels in Huntington disease. Arch Neurol. 1999;56(5):569–74.

    Not in our library10.1001/archneur.56.5.569

  50. 50.

    Lumsden AL Henshall TL Dayan S: Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet. 2007;16(16):1905–20.

    Not in our library10.1093/hmg/ddm138

  51. 51.
  52. 52.

    Yu J Qi F Wang N: Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: an in vivo MR study. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5–6):357–61.

    Not in our library10.3109/21678421.2014.906618

  53. 53.

    Lee JK Shin JH Gwag BJ: Iron accumulation promotes TACE-mediated TNF-α secretion and neurodegeneration in a mouse model of ALS. Neurobiol Dis. 2015;80:63–9.

    Not in our library10.1016/j.nbd.2015.05.009

  54. 54.

    Hadzhieva M Kirches E Wilisch-Neumann A: Dysregulation of iron protein expression in the G93A model of amyotrophic lateral sclerosis. Neuroscience. 2013;230:94–101.

    Not in our library10.1016/j.neuroscience.2012.11.021

  55. 55.

    Horning KJ Caito SW Tipps KG: Manganese Is Essential for Neuronal Health. Annu Rev Nutr. 2015;35:71–108.

    Not in our library10.1146/annurev-nutr-071714-034419

  56. 56.

    Chen P Chakraborty S Mukhopadhyay S: Manganese homeostasis in the nervous system. J Neurochem. 2015;134(4):601–10.

    Not in our library10.1111/jnc.13170

  57. 57.

    Michalke B Fernsebner K: New insights into manganese toxicity and speciation. J Trace Elem Med Biol. 2014;28(2):106–16.

    Not in our library10.1016/j.jtemb.2013.08.005

  58. 58.

    Gorell JM Rybicki BA Cole Johnson C: Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology. 1999;18(6):303–8.

    Not in our library10.1159/000026225

  59. 59.
  60. 60.

    Williams M Todd GD Roney N: Toxicological Profile for Manganese. Atlanta (GA): Agency for Toxic Substances and Disease Registry (US);2012 Sep.

    Not in our library

  61. 61.

    Karki P Smith K Johnson J Jr: Role of transcription factor yin yang 1 in manganese-induced reduction of astrocytic glutamate transporters: Putative mechanism for manganese-induced neurotoxicity. Neurochem Int. 2015;88:53–9.

    Not in our library10.1016/j.neuint.2014.08.002

  62. 62.

    Racette BA: Manganism in the 21st century: the Hanninen lecture. Neurotoxicology. 2014;45:201–7.

    Not in our library10.1016/j.neuro.2013.09.007

  63. 63.

    Robison G Sullivan B Cannon JR: Identification of dopaminergic neurons of the substantia nigra pars compacta as a target of manganese accumulation. Metallomics. 2015;7(5):748–55.

    Not in our library10.1039/c5mt00023h

  64. 64.

    Rudgalvyte M Peltonen J Lakso M: RNA-Seq Reveals Acute Manganese Exposure Increases Endoplasmic Reticulum Related and Lipocalin mRNAs in Caenorhabditis elegans. J Biochem Mol Toxicol. 2016;30(2):97–105.

    Not in our library10.1002/jbt.21768

  65. 65.

    Martinez-Finley EJ Gavin CE Aschner M: Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med. 2013;62:65–75.

    Not in our library10.1016/j.freeradbiomed.2013.01.032

  66. 66.

    Farina M Avila DS da Rocha JB: Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. Neurochem Int. 2013;62(5):575–94.

    Not in our library10.1016/j.neuint.2012.12.006

  67. 67.

    Gorojod RM Alaimo A Porte Alcon S: The autophagic- lysosomal pathway determines the fate of glial cells under manganese- induced oxidative stress conditions. Free Radic Biol Med. 2015;87:237–51.

    Not in our library10.1016/j.freeradbiomed.2015.06.034

  68. 68.

    Yousefi Babadi V Sadeghi L Shirani K: The toxic effect of manganese on the acetylcholinesterase activity in rat brains. J Toxicol. 2014;2014: 946372.

    Not in our library10.1155/2014/946372

  69. 69.

    Liang G Qin H Zhang L: Effects of chronic manganese exposure on the learning and memory of rats by observing the changes in the hippocampal cAMP signaling pathway. Food Chem Toxicol. 2015;83:261–7.

    Not in our library10.1016/j.fct.2015.07.005

  70. 70.

    Kwik-Uribe C Smith DR: Temporal responses in the disruption of iron regulation by manganese. J Neurosci Res. 2006;83(8):1601–10.

    Not in our library10.1002/jnr.20836

  71. 71.

    Roth JA Horbinski C Higgins D: Mechanisms of manganese-induced rat pheochromocytoma (PC12) cell death and cell differentiation. Neurotoxicology. 2002;23(2):147–57.

    Not in our library10.1016/s0161-813x(01)00077-8

  72. 72.

    Harischandra DS Jin H Anantharam V: α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease. Toxicol Sci. 2015;143(2):454–68.

    Not in our library10.1093/toxsci/kfu247

  73. 73.

    Anantharam V Kitazawa M Wagner J: Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J Neurosci. 2002;22(5):1738–51.

    Not in our library10.1523/jneurosci.22-05-01738.2002

  74. 74.

    Latchoumycandane C Anantharam V Kitazawa M: Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther. 2005;313(1):46–55.

    Not in our library10.1124/jpet.104.078469

  75. 75.

    Tuschl K Clayton PT Gospe SM Jr: Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. Am J Hum Genet. 2012;90(3):457–66.

    Not in our library10.1016/j.ajhg.2012.01.018

  76. 76.

    Stamelou M Tuschl K Chong WK: Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord. 2012;27(10):1317–22.

    Not in our library10.1002/mds.25138

  77. 77.

    Quadri M Federico A Zhao T: Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease. Am J Hum Genet. 2012;90(3):467–77.

    Not in our library10.1016/j.ajhg.2012.01.017

  78. 78.

    Choi CJ Anantharam V Saetveit NJ: Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death. Toxicol Sci. 2007;98(2):495–509.

    Not in our library10.1093/toxsci/kfm099

  79. 79.

    Choi CJ Anantharam V Martin DP: Manganese upregulates cellular prion protein and contributes to altered stabilization and proteolysis: relevance to role of metals in pathogenesis of prion disease. Toxicol Sci. 2010;115(2):535–46.

    Not in our library10.1093/toxsci/kfq049

  80. 80.

    Hambidge M: Human zinc deficiency. J Nutr. 2000;130(5S Suppl):1344S–9S.

    Not in our library10.1093/jn/130.5.1344s

  81. 81.

    Mizuno D Kawahara M: The molecular mechanisms of zinc neurotoxicity and the pathogenesis of vascular type senile dementia. Int J Mol Sci. 2013;14(11):22067–81.

    Not in our library10.3390/ijms141122067

  82. 82.

    Prasad AS: Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr. 2009;28(3):257–65.

    Not in our library10.1080/07315724.2009.10719780

  83. 83.

    Fosmire GJ: Zinc toxicity. Am J Clin Nutr. 1990;51(2):225–7.

    Not in our library10.1093/ajcn/51.2.225

  84. 84.

    Cuajungco MP Goldstein LE Nunomura A: Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem. 2000;275(26):19439–42.

    Not in our library10.1074/jbc.c000165200

  85. 85.

    Garai K Sahoo B Kaushalya SK: Zinc lowers amyloid-beta toxicity by selectively precipitating aggregation intermediates. Biochemistry. 2007;46(37):10655–63.

    Not in our library10.1021/bi700798b

  86. 86.

    Cuajungco MP Fagét KY: Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res Brain Res Rev. 2003;41(1):44–56.

    Not in our library10.1016/s0165-0173(02)00219-9

  87. 87.

    Jomova K Vondrakova D Lawson M: Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010;345(1–2):91–104.

    Not in our library10.1007/s11010-010-0563-x

  88. 88.

    Weiss JH Sensi SL Koh JY: Zn 2+: a novel ionic mediator of neural injury in brain disease. Trends Pharmacol Sci. 2000;21(10):395–401.

    Not in our library10.1016/s0165-6147(00)01541-8

  89. 89.

    Edwardson JA Candy JM Ince PG: Aluminium accumulation, beta-amyloid deposition and neurofibrillary changes in the central nervous system. Ciba Found Symp. 1992;169:165–79; discussion 179–85.

    Not in our library10.1002/9780470514306.ch10

  90. 90.

    Harrington CR Wischik CM McArthur FK: Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet. 1994;343(8904):993–7.

    Not in our library10.1016/s0140-6736(94)90124-4

  91. 91.

    Flendrig JA Kruis H Das HA, editors: Aluminium intoxication: the cause of dialysis dementia? Proc Eur Dial Transplant Assoc. 1976 Reference Source

    Not in our library

  92. 92.

    Wang Z Wei X Yang J: Chronic exposure to aluminum and risk of Alzheimer's disease: A meta-analysis. Neurosci Lett. 2016;610:200–6.

    Not in our library10.1016/j.neulet.2015.11.014

  93. 93.

    Lopes MM Caldas LQA: Young children with austim spectrum disorders: Can aluminium bodyburden cause metabolism disruption? Toxicol Lett. 2011;205(Supplement):S92

    Not in our library10.1016/j.toxlet.2011.05.338

  94. 94.

    De Marchi U Mancon M Battaglia V: Influence of reactive oxygen species production by monoamine oxidase activity on aluminum-induced mitochondrial permeability transition. Cell Mol Life Sci. 2004;61(19–20):2664–71.

    Not in our library10.1007/s00018-004-4236-3

  95. 95.

    Murakami K Yoshino M: Aluminum decreases the glutathione regeneration by the inhibition of NADP-isocitrate dehydrogenase in mitochondria. J Cell Biochem. 2004;93(6):1267–71.

    Not in our library10.1002/jcb.20261

  96. 96.

    Niu PY Niu Q Zhang QL: Aluminum impairs rat neural cell mitochondria in vitro. Int J Immunopathol Pharmacol. 2005;18(4):683–9.

    Not in our library10.1177/039463200501800410

  97. 97.

    Prakash C Soni M Kumar V: Mitochondrial oxidative stress and dysfunction in arsenic neurotoxicity: A review. J Appl Toxicol. 2016;36(2):179–88.

    Not in our library10.1002/jat.3256

  98. 98.

    Tolins M Ruchirawat M Landrigan P: The developmental neurotoxicity of arsenic: cognitive and behavioral consequences of early life exposure. Ann Glob Health. 2014;80(4):303–14.

    Not in our library10.1016/j.aogh.2014.09.005

  99. 99.

    Breuer C Oh J Nolkemper D: Successful detoxification and liver transplantation in a severe poisoning with a chemical wood preservative containing chromium, copper, and arsenic. Transplantation. 2015;99(4):e29–30.

    Not in our library10.1097/tp.0000000000000654

  100. 100.

    McClintock TR Chen Y Bundschuh J: Arsenic exposure in Latin America: biomarkers, risk assessments and related health effects. Sci Total Environ. 2012;429:76–91.

    Not in our library10.1016/j.scitotenv.2011.08.051

  101. 101.

    Aung KH Tsukahara S Maekawa F: Role of Environmental Chemical Insult in Neuronal Cell Death and Cytoskeleton Damage. Biol Pharm Bull. 2015;38(8):1109–12.

    Not in our library10.1248/bpb.b14-00890

  102. 102.
  103. 103.

    Zarazúa S Bürger S Delgado JM: Arsenic affects expression and processing of amyloid precursor protein (APP) in primary neuronal cells overexpressing the Swedish mutation of human APP. Int J Dev Neurosci. 2011;29(4):389–96.

    Not in our library10.1016/j.ijdevneu.2011.03.004

  104. 104.

    DeFuria J Shea TB: Arsenic inhibits neurofilament transport and induces perikaryal accumulation of phosphorylated neurofilaments: roles of JNK and GSK-3beta. Brain Res. 2007;1181:74–82.

    Not in our library10.1016/j.brainres.2007.04.019

  105. 105.

    Luevano J Damodaran C: A review of molecular events of cadmium-induced carcinogenesis. J Environ Pathol Toxicol Oncol. 2014;33(3):183–94.

    Not in our library10.1615/jenvironpatholtoxicoloncol.2014011075

  106. 106.
  107. 107.

    Bishak YK Payahoo L Osatdrahimi A: Mechanisms of cadmium carcinogenicity in the gastrointestinal tract. Asian Pac J Cancer Prev. 2015;16(1):9–21.

    Not in our library10.7314/apjcp.2015.16.1.9

  108. 108.

    Jiang LF Yao TM Zhu ZL: Impacts of Cd(II) on the conformation and self-aggregation of Alzheimer's tau fragment corresponding to the third repeat of microtubule-binding domain. Biochim Biophys Acta. 2007;1774(11):1414–21.

    Not in our library10.1016/j.bbapap.2007.08.014

  109. 109.

    Chow ES Hui MN Lin CC: Cadmium inhibits neurogenesis in zebrafish embryonic brain development. Aquat Toxicol. 2008;87(3):157–69.

    Not in our library10.1016/j.aquatox.2008.01.019

  110. 110.

    López E Figueroa S Oset-Gasque MJ: Apoptosis and necrosis: two distinct events induced by cadmium in cortical neurons in culture. Br J Pharmacol. 2003;138(5):901–11.

    Not in our library10.1038/sj.bjp.0705111

  111. 111.

    Radio NM Breier JM Shafer TJ: Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. Toxicol Sci. 2008;105(1):106–18.

    Not in our library10.1093/toxsci/kfn114

  112. 112.
  113. 113.

    Struzyñska L Bubko I Walski M: Astroglial reaction during the early phase of acute lead toxicity in the adult rat brain. Toxicology. 2001;165(2–3):121–31.

    Not in our library10.1016/s0300-483x(01)00415-2

  114. 114.

    Audesirk G: Electrophysiology of lead intoxication: effects on voltage-sensitive ion channels. Neurotoxicology. 1993;14(2–3):137–47.

    Not in our library

  115. 115.

    Zheng W Aschner M Ghersi-Egea JF: Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol. 2003;192(1):1–11.

    Not in our library10.1016/s0041-008x(03)00251-5

  116. 116.

    Selvín-Testa A Capani F Loidl CF: The nitric oxide synthase expression of rat cortical and hippocampal neurons changes after early lead exposure. Neurosci Lett. 1997;236(2):75–8.

    Not in our library10.1016/s0304-3940(97)00736-2

  117. 117.

    Nava-Ruiz C Méndez-Armenta M Ríos C: Lead neurotoxicity: effects on brain nitric oxide synthase. J Mol Histol. 2012;43(5):553–63.

    Not in our library10.1007/s10735-012-9414-2

  118. 118.

    Winneke G Lilienthal H Krämer U: The neurobehavioural toxicology and teratology of lead. Arch Toxicol Suppl. 1996;18:57–70.

    Not in our library10.1007/978-3-642-61105-6_7

  119. 119.

    Pocock SJ Smith M Baghurst P: Environmental lead and children's intelligence: a systematic review of the epidemiological evidence. BMJ. 1994;309(6963):1189–97.

    Not in our library10.1136/bmj.309.6963.1189

  120. 120.

    Baker EL Feldman RG White RF: The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. Acta Psychiatr Scand Suppl. 1983;303:38–48.

    Not in our library10.1111/j.1600-0447.1983.tb00940.x

  121. 121.

    Needleman HL Schell A Bellinger D: The long-term effects of exposure to low doses of lead in childhood. An 11-year follow-up report. N Engl J Med. 1990;322(2):83–8.

    Not in our library10.1056/nejm199001113220203

  122. 122.

    Campbell TF Needleman HL Riess JA: Bone lead levels and language processing performance. Dev Neuropsychol. 2000;18(2):171–86.

    Not in our library10.1207/s15326942dn1802_2

  123. 123.

    Stewart WF Schwartz BS: Effects of lead on the adult brain: a 15-year exploration. Am J Ind Med. 2007;50(10):729–39.

    Not in our library10.1002/ajim.20434

  124. 124.

    Parkinson DK Ryan C Bromet EJ: A psychiatric epidemiologic study of occupational lead exposure. Am J Epidemiol. 1986;123(2):261–9.

    Not in our library10.1093/oxfordjournals.aje.a114234

  125. 125.

    Li WC Tse HF: Health risk and significance of mercury in the environment. Environ Sci Pollut Res Int. 2015;22(1):192–201.

    Not in our library10.1007/s11356-014-3544-x

  126. 126.

    Parks JM Johs A Podar M: The genetic basis for bacterial mercury methylation. Science. 2013;339(6125):1332–5.

    Not in our library10.1126/science.1230667

  127. 127.

    Sheehan MC Burke TA Navas-Acien A: Global methylmercury exposure from seafood consumption and risk of developmental neurotoxicity: a systematic review. Bull World Health Organ. 2014;92(4):254–269F.

    Not in our library10.2471/blt.12.116152

  128. 128.

    Aschner M Aschner JL: Mercury neurotoxicity: mechanisms of blood-brain barrier transport. Neurosci Biobehav Rev. 1990;14(2):169–76.

    Not in our library10.1016/s0149-7634(05)80217-9

  129. 129.

    Kerper LE Ballatori N Clarkson TW: Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol. 1992;262(5 Pt 2):R761–5.

    Not in our library10.1152/ajpregu.1992.262.5.r761

  130. 130.

    Hong YS Kim YM Lee KE: Methylmercury exposure and health effects. J Prev Med Public Health. 2012;45(6):353–63.

    Not in our library10.3961/jpmph.2012.45.6.353

  131. 131.

    Davis LE Kornfeld M Mooney HS: Methylmercury poisoning: long-term clinical, radiological, toxicological, and pathological studies of an affected family. Ann Neurol. 1994;35(6):680–8.

    Not in our library10.1002/ana.410350608

  132. 132.

    Tiernan CT Edwin EA Hawong HY: Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase. Toxicol Sci. 2015;144(2):347–56.

    Not in our library10.1093/toxsci/kfv001

  133. 133.

    Tamm C Duckworth JK Hermanson O: Methylmercury inhibits differentiation of rat neural stem cells via Notch signalling. Neuroreport. 2008;19(3):339–43.

    Not in our library10.1097/wnr.0b013e3282f50ca4

  134. 134.

    Petroni D Tsai J Agrawal K: Low-dose methylmercury-induced oxidative stress, cytotoxicity, and tau-hyperphosphorylation in human neuroblastoma (SH-SY5Y) cells. Environ Toxicol. 2012;27(9):549–55.

    Not in our library10.1002/tox.20672

  135. 135.

    Sadiq S Ghazala Z Chowdhury A: Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects. J Toxicol. 2012;2012: 132671.

    Not in our library10.1155/2012/132671

  136. 136.

    Chang SH Lee HJ Kang B: Methylmercury induces caspase-dependent apoptosis and autophagy in human neural stem cells. J Toxicol Sci. 2013;38(6):823–31.

    Not in our library10.2131/jts.38.823

  137. 137.

    Yuntao F Chenjia G Panpan Z: Role of autophagy in methylmercury-induced neurotoxicity in rat primary astrocytes. Arch Toxicol. 2016;90(2):333–45.

    Not in our library10.1007/s00204-014-1425-1

  138. 138.

    Rice KM Walker EM Jr Wu M: Environmental mercury and its toxic effects. J Prev Med Public Health. 2014;47(2):74–83.

    Not in our library10.3961/jpmph.2014.47.2.74

  139. 139.

    Kim DK Park JD Choi BS: Mercury-induced amyloid-beta (Aβ) accumulation in the brain is mediated by disruption of Aβ transport. J Toxicol Sci. 2014;39(4):625–35.

    Not in our library10.2131/jts.39.625

  140. 140.

    Ser PH Watanabe C: Fish advisories in the USA and Japan: risk communication and public awareness of a common idea with different backgrounds. Asia Pac J Clin Nutr. 2012;21(4):487–94.

    Not in our library

  141. 141.
  142. 142.

    Galván-Arzate S Santamaría A: Thallium toxicity. Toxicol Lett. 1998;99(1):1–13.

    Not in our library10.1016/s0378-4274(98)00126-x

  143. 143.

    Cvjetko P Cvjetko I Pavlica M: Thallium toxicity in humans. Arh Hig Rada Toksikol. 2010;61(1):111–9.

    Not in our library10.2478/10004-1254-61-2010-1976

  144. 144.

    Saha A: Thallium toxicity: A growing concern. Indian J Occup Environ Med. 2005;9(2):53–56.

    Not in our library10.4103/0019-5278.16741

  145. 145.

    Zhao G Ding M Zhang B: Clinical manifestations and management of acute thallium poisoning. Eur Neurol. 2008;60(6):292–7.

    Not in our library10.1159/000157883

  146. 146.

    Pelclová D Urban P Ridzon P: Two-year follow-up of two patients after severe thallium intoxication. Hum Exp Toxicol. 2009;28(5):263–72.

    Not in our library10.1177/0960327109106487

  147. 147.

    McCormack J McKinney W: Thallium poisoning in group assassination attempt. Postgrad Med. 1983;74(6):239–41, 244.

    Not in our library10.1080/00325481.1983.11698545

  148. 148.

    Repetto G Sanz P Repetto M: In vitro effects of thallium on mouse neuroblastoma cells. Toxicol In Vitro. 1994;8(4):609–11.

    Not in our library10.1016/0887-2333(94)90028-0

  149. 149.

    Ibrahim D Froberg B Wolf A: Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med. 2006;26(1):67–97, viii.

    Not in our library10.1016/j.cll.2006.02.003

  150. 150.

    Ríos C Galván-Arzate S Tapia R: Brain regional thallium distribution in rats acutely intoxicated with Tl 2SO 4. Arch Toxicol. 1989;63(1):34–7.

    Not in our library10.1007/bf00334631

  151. 151.

    Eskandari MR Mashayekhi V Aslani M: Toxicity of thallium on isolated rat liver mitochondria: the role of oxidative stress and MPT pore opening. Environ Toxicol. 2015;30(2):232–41.

    Not in our library10.1002/tox.21900

  152. 152.

    Hasan M Ali SF Tariq M: Levels of dopamine, norepinephrine and 5-hydroxytryptamine in different regions of the rat brain in thallium toxicosis. Acta Pharmacol Toxicol (Copenh). 1978;43(3):169–73.

    Not in our library10.1111/j.1600-0773.1978.tb02251.x

  153. 153.

    Li JM Wang W Lei S: Misdiagnosis and long-term outcome of 13 patients with acute thallium poisoning in China. Clin Toxicol (Phila). 2014;52(3):181–6.

    Not in our library10.3109/15563650.2014.892123

  154. 154.

    Sanders AP Claus Henn B Wright RO: Perinatal and Childhood Exposure to Cadmium, Manganese, and Metal Mixtures and Effects on Cognition and Behavior: A Review of Recent Literature. Curr Environ Health Rep. 2015;2(3):284–94.

    Not in our library10.1007/s40572-015-0058-8

  155. 155.

    McDermott S Wu J Cai B: Probability of intellectual disability is associated with soil concentrations of arsenic and lead. Chemosphere. 2011;84(1):31–8.

    Not in our library10.1016/j.chemosphere.2011.02.088

  156. 156.

    Kim Y Ha E Park H: Prenatal lead and cadmium co-exposure and infant neurodevelopment at 6 months of age: the Mothers and Children's Environmental Health (MOCEH) study. Neurotoxicology. 2013;35:15–22.

    Not in our library10.1016/j.neuro.2012.11.006

  157. 157.

    Lin CC Chen YC Su FC: In utero exposure to environmental lead and manganese and neurodevelopment at 2 years of age. Environ Res. 2013;123:52–7.

    Not in our library10.1016/j.envres.2013.03.003

  158. 158.

    Kim Y Kim BN Hong YC: Co-exposure to environmental lead and manganese affects the intelligence of school-aged children. Neurotoxicology. 2009;30(4):564–71.

    Not in our library10.1016/j.neuro.2009.03.012

  159. 159.

    Yorifuji T Debes F Weihe P: Prenatal exposure to lead and cognitive deficit in 7- and 14-year-old children in the presence of concomitant exposure to similar molar concentration of methylmercury. Neurotoxicol Teratol. 2011;33(2):205–11.

    Not in our library10.1016/j.ntt.2010.09.004

  160. 160.

    Kalia K Murthy RC Chandra SV: Tissue disposition of 54Mn in lead pretreated rats. Ind Health. 1984;22(1):49–52.

    Not in our library10.2486/indhealth.22.49

  161. 161.

    Chandra SV Murthy RC Saxena DK: Effects of pre- and postnatal combined exposure to Pb and Mn on brain development in rats. Ind Health. 1983;21(4):273–9.

    Not in our library10.2486/indhealth.21.273

  162. 162.

    Mejía JJ Díaz-Barriga F Calderón J: Effects of lead-arsenic combined exposure on central monoaminergic systems. Neurotoxicol Teratol. 1997;19(6):489–97.

    Not in our library10.1016/s0892-0362(97)00066-4

  163. 163.

    Rodríguez VM Dufour L Carrizales L: Effects of oral exposure to mining waste on in vivo dopamine release from rat striatum. Environ Health Perspect. 1998;106(8):487–91.

    Not in our library10.1289/ehp.106-1533203

  164. 164.

    Andrade V Mateus ML Batoréu MC: Changes in rat urinary porphyrin profiles predict the magnitude of the neurotoxic effects induced by a mixture of lead, arsenic and manganese. Neurotoxicology. 2014;45:168–77.

    Not in our library10.1016/j.neuro.2014.10.009

  165. 165.

    Hambidge KM Sokol RJ Fidanza SJ: Plasma manganese concentrations in infants and children receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. 1989;13(2):168–71.

    Not in our library10.1177/0148607189013002168

  166. 166.

    Jang DH Hoffman RS: Heavy metal chelation in neurotoxic exposures. Neurol Clin. 2011;29(3):607–22.

    Not in our library10.1016/j.ncl.2011.05.002

  167. 167.

    Leyva-Illades D Chen P Zogzas CE: SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity. J Neurosci. 2014;34(42):14079–95.

    Not in our library10.1523/jneurosci.2329-14.2014

  168. 168.

    Chen P Bowman AB Mukhopadhyay S: SLC30A10: A novel manganese transporter. Worm. 2015;4(3):e1042648.

    Not in our library10.1080/21624054.2015.1042648

Cited by papers we hold 5

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.